See more : Vatti Corporation Limited (002035.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Valneva SE (VALN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Valneva SE, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Mesa Laboratories, Inc. (MLAB) Income Statement Analysis – Financial Results
- Highlight Event and Entertainment AG (0QL0.L) Income Statement Analysis – Financial Results
- Smartbroker Holding AG (SB1.BE) Income Statement Analysis – Financial Results
- CVS Health Corporation (CVS.DE) Income Statement Analysis – Financial Results
- Jain Irrigation Systems Limited (JISLJALEQS.BO) Income Statement Analysis – Financial Results
Valneva SE (VALN)
About Valneva SE
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 153.71M | 361.30M | 348.09M | 110.32M | 126.20M | 113.04M | 105.29M | 94.06M | 78.36M | 36.92M | 30.45M | 3.43M | 10.26M | 8.40M | 3.10M | 3.42M | 866.00K | 2.33M | 3.01M |
| Cost of Revenue | 100.88M | 324.44M | 187.92M | 54.30M | 49.97M | 43.43M | 45.98M | 43.08M | 46.96M | 17.14M | 16.51M | 11.10M | 6.72M | 6.54M | 5.26M | 2.75M | 1.68M | 726.00K | 475.00K |
| Gross Profit | 52.84M | 36.86M | 160.17M | 56.02M | 76.23M | 69.60M | 59.31M | 50.99M | 31.40M | 19.78M | 13.94M | -7.66M | 3.54M | 1.86M | -2.16M | 673.00K | -817.00K | 1.60M | 2.54M |
| Gross Profit Ratio | 34.37% | 10.20% | 46.01% | 50.78% | 60.40% | 61.58% | 56.33% | 54.20% | 40.07% | 53.57% | 45.78% | -223.38% | 34.50% | 22.11% | -69.80% | 19.69% | -94.34% | 68.83% | 84.22% |
| Research & Development | 59.89M | 104.92M | 173.28M | 84.45M | 37.88M | 12.19M | 23.36M | 24.59M | 25.37M | 22.24M | 21.42M | 12.89M | 12.17M | 13.13M | 9.87M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 47.80M | 34.07M | 47.61M | 38.01M | 27.51M | 36.30M | 15.55M | 14.41M | 14.39M | 14.14M | 14.72M | 4.18M | 262.00K | 3.69M | 3.06M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 48.75M | 23.51M | 23.64M | 7.52M | 14.62M | 11.74M | 17.88M | 16.64M | 9.12M | 2.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 96.55M | 57.58M | 71.25M | 45.52M | 42.13M | 48.04M | 33.42M | 31.05M | 23.52M | 14.14M | 14.72M | 4.18M | 262.00K | 3.69M | 3.06M | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | -21.52M | -12.20M | -22.98M | -18.85M | -3.07M | 19.83M | 6.49M | 37.79M | 2.48M | 7.15M | -91.00K | -798.00K | 8.39M | -636.00K | 3.38M | 3.83M | 3.97M | 1.82M | 3.97M |
| Operating Expenses | 134.92M | 150.31M | 221.56M | 111.13M | 76.95M | 63.34M | 63.27M | 93.43M | 51.36M | 43.53M | 36.05M | 16.26M | 8.65M | 16.81M | 3.38M | 3.83M | 3.97M | 1.82M | 3.97M |
| Cost & Expenses | 235.80M | 474.75M | 409.48M | 165.43M | 126.92M | 106.77M | 109.25M | 136.51M | 98.32M | 60.68M | 52.56M | 16.26M | 15.37M | 16.81M | 8.64M | 6.57M | 5.65M | 2.55M | 4.44M |
| Interest Income | 1.21M | 260.00K | 249.00K | 119.00K | 199.00K | 178.00K | 72.00K | 290.00K | 3.10M | 225.00K | 191.00K | 435.00K | 757.00K | 389.00K | 312.00K | 972.00K | 550.00K | 91.00K | 34.00K |
| Interest Expense | 23.33M | 19.05M | 16.96M | 10.74M | 2.63M | 3.79M | 5.06M | 6.09M | 9.72M | 4.39M | 1.21M | 533.00K | 699.00K | 786.00K | 161.00K | 207.00K | 154.00K | 25.00K | 81.00K |
| Depreciation & Amortization | 17.58M | 21.04M | 14.28M | 9.80M | 8.53M | 6.83M | 11.14M | 11.27M | 11.44M | 12.36M | 9.06M | 4.78M | 3.32M | 2.62M | 1.59M | 1.31M | 1.22M | 328.00K | 1.52M |
| EBITDA | -57.72M | -99.39M | -46.87M | -46.11M | 9.71M | 12.85M | 3.64M | -31.47M | 9.76M | -9.19M | -13.36M | -7.69M | 795.00K | -6.08M | -4.70M | -1.82M | -3.02M | 605.00K | 998.00K |
| EBITDA Ratio | -37.55% | -31.32% | -13.46% | -41.08% | 8.01% | 12.74% | 6.98% | -0.97% | -1.58% | -30.38% | -42.13% | -220.69% | -10.04% | -69.04% | -127.58% | -53.31% | -348.50% | 23.06% | 30.89% |
| Operating Income | -82.09M | -113.44M | -61.39M | -55.11M | 1.50M | 6.26M | -3.95M | -42.57M | -19.93M | -23.82M | -20.86M | -12.83M | -4.45M | -8.42M | -6.30M | -3.15M | -4.79M | -221.00K | -1.43M |
| Operating Income Ratio | -53.40% | -31.40% | -17.64% | -49.95% | 1.19% | 5.54% | -3.76% | -45.26% | -25.44% | -64.50% | -68.50% | -374.03% | -43.37% | -100.26% | -203.33% | -92.28% | -552.54% | -9.49% | -47.49% |
| Total Other Income/Expenses | -16.54M | -31.37M | -8.59M | -10.18M | -59.00K | -2.91M | -8.61M | -6.26M | -13.64M | -2.12M | -2.77M | -56.00K | 1.43M | -397.00K | 3.58M | 765.00K | 396.00K | -25.00K | 34.00K |
| Income Before Tax | -98.63M | -144.82M | -69.98M | -65.30M | -870.00K | 3.35M | -12.56M | -48.83M | -20.39M | -25.94M | -23.63M | -12.89M | -4.39M | -9.45M | -6.14M | -2.39M | -4.39M | -246.00K | -1.40M |
| Income Before Tax Ratio | -64.16% | -40.08% | -20.10% | -59.19% | -0.69% | 2.96% | -11.93% | -51.91% | -26.03% | -70.25% | -77.60% | -375.66% | -42.80% | -112.57% | -198.45% | -69.89% | -506.81% | -10.56% | -46.36% |
| Income Tax Expense | 2.80M | -1.54M | 3.45M | -909.00K | 874.00K | 88.00K | -1.08M | 356.00K | 224.00K | 334.00K | 348.00K | 96.00K | 26.00K | -1.49M | 0.00 | 24.00K | -1.03M | -3.00K | -176.00K |
| Net Income | -101.43M | -143.28M | -73.43M | -64.39M | -1.74M | 3.26M | -11.48M | -49.18M | -20.62M | -26.27M | -24.11M | -14.84M | -4.42M | -7.96M | -6.14M | -2.39M | -3.36M | -243.00K | -1.22M |
| Net Income Ratio | -65.99% | -39.66% | -21.09% | -58.37% | -1.38% | 2.89% | -10.91% | -52.29% | -26.31% | -71.15% | -79.19% | -432.56% | -43.06% | -94.84% | -198.45% | -69.89% | -388.22% | -10.43% | -40.52% |
| EPS | -1.46 | -2.48 | -1.50 | -1.42 | -0.04 | 0.08 | -0.30 | -1.32 | -0.56 | -0.94 | -1.22 | -1.40 | -0.42 | -0.92 | -0.84 | -0.28 | -0.52 | -0.05 | -0.24 |
| EPS Diluted | -1.46 | -2.48 | -1.50 | -1.42 | -0.04 | 0.08 | -0.30 | -1.32 | -0.56 | -0.94 | -1.22 | -1.40 | -0.42 | -0.92 | -0.84 | -0.28 | -0.52 | -0.05 | -0.24 |
| Weighted Avg Shares Out | 69.31M | 57.74M | 48.81M | 45.38M | 45.87M | 40.26M | 38.27M | 37.33M | 36.37M | 27.75M | 19.67M | 10.63M | 10.50M | 8.75M | 7.31M | 8.42M | 6.53M | 5.10M | 5.10M |
| Weighted Avg Shares Out (Dil) | 69.31M | 57.74M | 48.81M | 45.38M | 45.87M | 40.80M | 38.72M | 37.33M | 36.37M | 27.75M | 19.67M | 10.63M | 10.54M | 8.75M | 7.31M | 8.42M | 6.53M | 5.10M | 5.10M |
Valneva Hosts Investor Day in New York City
Live event and webcast TODAY at 10 AM ET Saint Herblain (France), October 10, 2024 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, is hosting an investor day today in New York City to discuss the Company's...
Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET
Saint Herblain (France), October 3, 2024 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will host an investor day at the Lotte New York Palace Hotel in New York, NY on Thursday, October...
Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada
To potentially include adolescents and antibody persistence up to two years Saint Herblain (France), September 18, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted label extension applications to the...
Valneva Announces the Success of its Private Placement Raising approximately €60 Million
Saint-Herblain (France), September 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces the successful pricing of its Private Placement (as defined below) for a final amount of €61,180,000.
Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros
Saint-Herblain (France), September 12, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces its intention to issue, subject to market conditions, approximately 22.6 million new ordinary shares (the “Offer Shares”)...
Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock
Valneva and Pfizer report positive immunogenicity and safety data from their Phase 2 study of the VLA15 vaccine. Phase 3 trials for VLA15 are in progress.
Pfizer and Valneva report positive results in mid-stage trial of Lyme disease vaccine
The Phase 2 trial was evaluating the vaccine called VLA15 following a second booster dose given one year after the first one.
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate
Saint-Herblain (France) and New York, NY, September 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. (NYSE: PFE) announced today positive immunogenicity and safety data from their VLA15-221 Phase 2 study following a second booster vaccination of their Lyme disease...
Wall Street Analysts Predict a 150.41% Upside in Valneva (VALN): Here's What You Should Know
The consensus price target hints at a 150.4% upside potential for Valneva (VALN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside...
How Much Upside is Left in Valneva (VALN)? Wall Street Analysts Think 135.3%
The consensus price target hints at a 135.3% upside potential for Valneva (VALN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside...
Source: https://incomestatements.info
Category: Stock Reports